Publications by authors named "A Minguez-Olaondo"
Background And Purpose: The US Headache Consortium developed evidence-based guidelines for the treatment of migraine and found grade A evidence in support of behavior therapy (BT). Understanding the mechanisms of BT may improve the management of migraine and reduce its burden.
Methods: We performed a narrative review to define the current evidence of BT and determine its usefulness in migraine management.
Purpose: Migraine is the comorbidity most frequently associated with visual snow syndrome (VSS), but the prevalence of VSS in patients with migraine (PWM) has not been studied. Our objective was to evaluate the frequency of VSS in PWM and to analyze if symptoms of VSS happened in a permanent or episodic manner (eVSS) in this population.
Methods: We conducted a multicenter observational cross-sectional study.
Article Synopsis
- Primary intracranial pressure disorders, such as idiopathic intracranial hypertension and spontaneous intracranial hypotension, have seen significant advancements in diagnosis and treatment recently.
- The Spanish Society of Neurology's Headache Study Group (GECSEN) created a consensus statement with diagnostic and therapeutic algorithms to enhance management in clinical settings.
- This document is based on expert input and a systematic literature review, providing practical recommendations supported by levels of evidence and grades of recommendation.
Treatment of migraine attacks is advised in all patients, using non-steroidal anti-inflammatory drugs when the pain is mild and triptans when the pain intensity is moderate-severe. However, the effectiveness of these drugs is moderate, a high percentage of patients have side effects, and triptans are contraindicated in people with a history of stroke, ischaemic heart disease or poorly controlled hypertension. Hence, there is an urgent need for new therapeutic alternatives.
View Article and Find Full Text PDFBackground: Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and tolerability of galcanezumab in clinical practice in patients excluded from RCTs.
Methods: Multicenter prospective cohort study of consecutive patients with chronic and high-frequency episodic migraine (HFEM) with prior failure to three or more migraine preventive drugs, treated with galcanezumab and followed up for 12 months.